Association of internalizing disorders and allergies in a child and adolescent psychiatry clinical sample
ABSTRACT To investigate the specificity of the association between internalizing disorders (anxiety and depression) and atopic disorders (asthma, allergic rhinitis, urticaria, and atopic dermatitis) in a child and adolescent psychiatric clinical sample.
A sample of 184 youths was evaluated for current DSM-IV psychiatric disorders (clinical interview) and lifetime history of atopic disorders (parent report and chart review) in a child and adolescent psychiatry clinic from September 1, 2001, through December 31, 2002. Logistic regression analyses were used to assess the differential likelihood of having a lifetime history of atopic disorders among psychiatrically ill youths with and without internalizing disorders.
Youths with internalizing disorders were significantly more likely than those with noninternalizing disorders to have a lifetime history of atopic disorders (odds ratio [OR] = 1.95, 95% CI = 1.02 to 3.73, p = .04). Moreover, analyses distinguishing youths with "pure" internalizing disorders from those with comorbid internalizing and externalizing disorders, "pure" externalizing disorders, and other psychiatric disorders showed that the association with atopic disorders was specific for "pure" internalizing disorders only (OR = 2.40, 95% CI = 1.09 to 5.30, p = .03).
Atopic disorders may be associated specifically with "pure" internalizing disorders in psychiatrically ill youths. Additional studies are needed to identify the underlying mechanisms of this specificity for the subsequent development of effective treatment and prevention interventions that target both disorders.
- SourceAvailable from: Marilyn J Essex
[Show abstract] [Hide abstract]
- "However, the association of lifetime history of any atopic disorder with depression symptoms remained non-significant when anxiety and externalizing symptoms were controlled. Together, these results suggest that a lifetime history of any atopic disorder is associated more specifically with " pure " generalized anxiety symptoms rather than those co-occurring with either depression symptoms or, as we have previously shown (Infante et al., 2007), with externalizing symptoms. Thus, for the remaining analyses, externalizing symptoms and either depression (for analyses with anxiety as the dependent variable) or anxiety (for analyses with depression as the dependent variable) symptoms were controlled. "
ABSTRACT: The specificity of relationships between anxiety and depressive symptoms, with each of the major atopic disorders of asthma, allergic rhinitis (AR), and atopic dermatitis (AD) was systematically investigated within a single study sample. Participants included 367 adolescents who participated in a community, longitudinal study investigating risk factors for the development of psychiatric and physical health problems. Mental health symptoms were assessed at 7, 9, 11, and 13 years of age. Lifetime history of atopic disorders was assessed by parent report at age 13. Analysis of variance was used to investigate the specificity of the associations between anxiety and depression, and each of the atopic disorders. Results indicated that anxiety was associated with a lifetime history of atopic disorders as a group. The association was significantly strengthened when controlling for depression and externalizing psychiatric symptoms. Among atopic disorders, "pure" anxiety was associated with asthma and AR, and having both asthma and AR strengthened the association compared to having either disorder alone. The association of "pure" anxiety with asthma and AR is consistent with existing data suggesting a relationship between anxiety and respiratory disorders. Having both asthma and AR appeared to confer an additive "dose effect" on the strength of the association. The lack of an association with depression suggests that other factors may contribute to the differential expression of anxiety and depression with atopic disorders. Findings demonstrate the importance of assessing the impact of co-morbid psychiatric symptoms and atopic disorders within individual studies to determine the specificity of underlying relationships between these conditions.Journal of Psychiatric Research 11/2010; 45(6):788-95. DOI:10.1016/j.jpsychires.2010.11.003 · 4.09 Impact Factor
- [Show abstract] [Hide abstract]
ABSTRACT: Psicosomática de la Escuela de Psicoanálisis Grupo Cero en los últimos 9 años, lugar de investigación teórica y clínica, del que las moderadoras son profesoras y los participantes en la mesa integrantes del Seminario. Hemos elegido el tema de la inmunidad, porque sus alteraciones producen una gama muy amplia de enfermedades con afectación sistémica, desde las alergias, donde el sistema inmune responde inadecuadamente, reconociendo como nociva a una sustancia que no lo es y reaccionando exageradamente frente a ella, hasta el cáncer, donde el fallo de la inmunovigilancia, tiene un impacto directo en el desarrollo de la enfermedad tumoral, pasando por la autoinmunidad, donde el sistema reacciona atacando lo propio, el propio cuerpo. Se planteará los distintos temas de la mesa desde un enfoque médico y psicoanalítico.
- [Show abstract] [Hide abstract]
ABSTRACT: To examine the long-term effects of the methylphenidate transdermal system (MTS) on the growth of children being treated for attention-deficit/hyperactivity disorder. Height, weight, and body mass index (BMI) were measured in 127 children ages 6 to 12 at longitudinal assessments for up to 36 months of treatment with MTS. These data were compared with norms provided by the Centers for Disease Control and Prevention. MTS treatment was associated with small but significant delays in growth for height, weight, and BMI. The latter two indices were affected in a dose-dependent manner. Children who had not received prior stimulant therapy and children who entered the study with above-average height, weight, and BMI were most likely to experience growth deficits during the trial. Effects on all parameters of growth were most apparent during the first year of treatment, and attenuated over time. Consistent with prior studies of methylphenidate, our results suggest that treatment with MTS can lead to reductions in expected height, weight, and BMI that show some attenuation over the course of treatment. Growth of patients with attention-deficit/hyperactivity disorder treated with MTS should be closely monitored, but in this study, deficits in growth in relation to MTS treatment were not a significant clinical concern for most children.Journal of the American Academy of Child & Adolescent Psychiatry 10/2007; 46(9):1138-47. DOI:10.1097/chi.0b013e31806ad1d7 · 6.35 Impact Factor